Loading
A phase 2 trial of SAR445877 in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Sanofi, now recruiting.
A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer is a phase 2 interventional study registered as NCT07692204 by Sanofi, with 30 participants planned, started 2026-07-01 and due to reach its primary completion in 2028-08-02. Interventions recorded: SAR445877.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/